View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
January 20, 2022

Signant to serve as technology vendor for Trials@Home consortium

The research project is funded by the EU/EFPIA’s Innovative Medicines Initiative Joint Undertaking.

Trials@Home consortium has selected Signant Health as a technology vendor for a five-year research project to develop recommendations for decentralised clinical trials (DCTs) implementation in Europe.

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

By developing and piloting tools, standards, and best practices for DCTs, the project is targeting to redesign clinical trials in the European Union (EU).

The project, which is funded by the EU/EFPIA’s Innovative Medicines Initiative Joint Undertaking (H2020-JTI-IMI2), is divided into six focus areas.

These focus areas will be led by different consortium members who work in commercial, academic, and governmental organisations.

The consortium selected Signant’s SmartSignals randomization and trial supply management (RTSM) and Telemedicine solutions as they can enable complete remote and hybrid clinical trials.

These two solutions also have the ability to integrate with the complex vendor ecosystem to support the clinical study.

Signant Health chief operating officer Jason Martin said: “We’re proud to be selected for this important research project which will help lay the groundwork for new study conduct options in Europe.

“The recommendations and best practices that we will establish in collaboration with Trials@Home consortium partners will allow medical researchers in Europe to take advantage of exponential digitalization to accelerate and streamline clinical development processes.”

The company will provide a direct-to-patient (DtP) model of its solutions for a proof-of-concept study, which is known as the RADIAL trial.

Across 63 sites in eight countries, the 12-month study aims to recruit 800 subjects with type 2 diabetes.

In the trial, the operational and scientific quality of the complete decentralised and hybrid models will be compared with a conventional study to assess the feasibility of such methods.

The trial is planned to begin this year and results, recommendations, and tools are anticipated in 2024.

In June 2020, Signant Health expanded its mobile patient engagement app, TrialGuide, with integrated virtual visit capabilities.

Related Companies

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena